About Precision Therapeutics
Over the years, there have been many challenges in determining the best course of therapy for an individual cancer patient. The basic problem is that patients with similar diagnoses don’t always respond to the same chemotherapy, schedule, or dose. Additionally, ineffective therapies and tumors that have no established standard of care make it difficult for cancer specialists to decide upon an appropriate course of treatment. With this in mind, a group of scientists established Precision Therapeutics in 1995, with the sole aim of developing and delivering technology that could help a physician select the appropriate chemotherapy for an individual patient—giving them an edge in the fight against cancer.
Precision Medicine: Therapy as individual as the cancers themselves
Precision, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach to precision medicine, combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®
, is a proprietary chemoresponse marker which helps improve patient outcomes by supporting physicians in the selection of effective treatments for women with gynecologic cancer. Recently published studies demonstrate a 14-month improvement in median overall survival when ovarian cancer patients are treated with sensitive therapies as identified by ChemoFx®
and show ChemoFx®
is predictive of treatment-specific outcome. Since 2010, Precision has recieved more than 50,000 gynecologic cancer patient specimens for ChemoFx®
testing from over 1,000 US hospitals, including nine of the US News and World Report Top 10 Hospitals for Cancer Care and 23/25 National Comprehensive Cancer Network (NCCN) Member Institutions.
Research that leads to developments
As a leading force in research, Precision Therapeutics is committed to the development of precision medicine support tools and services for individualized cancer treatment. To underscore this commitment, Precision Therapeutics has commissioned and funded multiple clinical research programs in partnership with leading medical research institutes. And we will continue to investigate methods that will facilitate the effective delivery of individualized cancer therapy—giving physicians and patients an edge in the fight against cancer.
In the lab
Precision Therapeutics’ laboratories are fully equipped to perform tissue culture-based analysis. Our laboratories have been certified to comply with the Centers for Medicare & Medicaid Services CLIA (Clinical Laboratory Improvement Amendments) program, and are licensed by the Pennsylvania Department of Health and the New York State Department of Health. Our scientific staff has extensive experience in clinical testing, precision medicine and cancer research and provides services to physicians throughout the United States and Canada from our headquarters in Pittsburgh, Pennsylvania.